[276 Pages Report] The global swine respiratory diseases treatment market size is expected to reach a valuation of US$ 2.0 Billion by the end of 2022, and further expand at a CAGR of 6.3% from 2022 to 2032. The market is likely to reach a valuation of US$ 3.6 Billion by the end of 2032. Mycoplasma under the causative agent segment is leading the swine respiratory diseases treatment market and it held a share of about 35.2% in 2021.
Based on the severity and duration of the observable condition, swine respiratory disorders can be grouped into two main categories: those that affect a significant number of pigs and may be hazardous but only last a short while, and those that affect a large number of pigs for an extended period of time. Costs of diseases in the first category are limited rather than continuing.
Swine influenza, classical swine fever, pneumonic pseudorabies, porcine circovirus-associated illness, and pig reproductive and respiratory syndrome (PRRS) are categorized among them. Although pathogenic viruses may survive in a herd, outbreaks of overt sickness are usually self-limiting. Mycoplasma pneumonia and pleuropneumonia are the most common syndromes in the second category like rhinitis atrophic.
| Attributes | Key Statistics |
|---|---|
| Global Swine Respiratory Diseases Treatment Market Estimated Size (2022E) | US$ 1,978.1 Million |
| Projected Market Valuation (2032F) | US$ 3,649.5 Million |
| Value-based CAGR (2022 to 2032) | 6.3% |
| Collective Value Share: Top 5 Countries | 61.4% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global swine respiratory diseases treatment market held approximately 1.9% of the overall veterinary services market, which was worth ~US$ 99.5 Billion in 2021. Sales of swine respiratory disease treatment services expanded at a CAGR of 6.1% from 2012 to 2021.
Demand for swine respiratory disease treatment options is on the rise due to the increasing number of foodborne and zoonotic diseases. According to the most recent annual report on food diseases issued by the European Food Safety Authority (EFSA) and the European Center for Disease Prevention and Control (ECDC) in February 2021, foodborne infections are on the rise compared to the previous year, with pathogenic bacteria such as campylobacter spp. being the most common cause.
Around 5175 food outbreaks were documented, accounting for 49463 clinical cases, 3859 hospital admissions, and 60 deaths (+50% compared to the previous year). Salmonella, norovirus, escherichia coli, yersinia enterocolitica, cryptosporidium parvum, and campylobacter jejuni were the most common etiological agents found, while the most common causes of infection were eggs & egg products, bakery items, hog meat, processed foods, water, crustaceans, and vegetables.
Additionally, the market for swine respiratory diseases treatment is anticipated to grow in terms of research & development (R&D) spending and revenue owing to external partnerships and strategic alliances between industries and academia. For instance, in September 2022, Zoetis acquired NewMetrica, which had developed cutting-edge digital instruments in the form of standardized questionnaires that were intended to evaluate health-related quality of life (HRQL) in nonverbal species, as a strategic addition to their companion animal portfolio. Thus, owing to the aforementioned factors, the global swine respiratory diseases treatment market is expected to grow at a CAGR of 6.3% during the forecast period from 2022 to 2032.
The market is likely to provide an opportunistic perspective owing to various initiatives by governments in emerging countries. Government bodies are investing significantly in healthcare infrastructure modernization, which is expected to bolster access to advanced healthcare services. This factor is set to fuel demand for upgraded technologies, thereby creating an appealing opportunity in the global swine respiratory diseases treatment market.
In high-income economies like the UK and the USA, there will likely be a greater emphasis on innovation to prevent zoonotic diseases combined with biotechnology breakthroughs, which will create a favorable environment for the development of veterinary therapeutics. These methods include systems biology, synthetic biology, and next-generation sequencing among others. Additionally, maintaining investments in multidisciplinary research may accelerate the time to market for new products and enhance the efficiency of therapy development.
The large market potential for veterinary therapeutics is expected to emerge throughout the forecast period as a result of growing economies in emerging markets like Latin America and Asia Pacific. The potential that these markets present are due to a large number of factors, including the increasing cost of living for the urban middle-class population in these regions, which further surges per-capita meat consumption and fuels the need for more effective livestock farming.
Principal Consultant
Stringent regulations put forward by the USA Food & Drug Administration (FDA) to limit the use of antibiotics for farm animals and the rising cost of innovation-dampening Research and Development investments can hamper the market in the forecast period. If antibiotics are administered to livestock that is raised for food such as swine and other animals, they may lose their efficacy in humans. Antibiotic-resistant bacteria known as superbugs are on the rise as a result of the widespread use of antibiotics in both humans and animals.
The cost of drug innovation has been increasing, as compared to earlier years. The trend is similar for animal healthcare. This is primarily attributed to a limited scope of research for newer diseases in livestock animals. Due to this, drug makers are investing more in the development of innovative drugs for diseases, which are already highly mature. This further raises Research and Development spending and dampens return on investment (ROI). These factors cumulatively propose a negative effect on developmental growth in the swine respiratory diseases treatment market.
Rising Prevalence of Zoonotic Diseases in the USA to Push Growth by 2032
The USA dominates the North American swine respiratory diseases treatment market and held a total share of about 52.9% in 2021. It is expected to continue to experience the same growth rate throughout the forecast period.
Owing to the increased swine respiratory diseases related deaths, high consumption of animal meats, and growing prevalence of zoonotic diseases, producers or manufacturers operating in the market are presented with new growth opportunities to develop unique preventive measures, which would further boost the market in the USA
Surging Need for H1N1 Influenza Treatment in Canada to Drive the Industry Forward
Canada held approximately 47.1% of the share in the North American swine respiratory diseases treatment market in 2021 and it is expected to showcase growth at a lucrative CAGR of 6.7% during the forecast period.
Influenza viruses are frequently found in pigs, who can be infected by humans, birds, or other pigs. Predominant influenza subtypes prevalent in pigs in Canada are H1N1, H1N2, and H3N2. Swine influenza viruses do not generally infect humans; however, these viruses have occasionally infected humans.
Cases mainly emerge because of direct or indirect contact with pigs in numerous settings such as farms or agricultural fairs. The Canadian Food Inspection Agency (CFIA) advises veterinarians and producers to maintain strict biosecurity measures to reduce any hazards to human or animal health.
Rising Cases of Swine Fever in Pigs to Propel Growth in Germany by 2032
Germany is set to exhibit a CAGR of nearly 5.8% in the Europe swine respiratory diseases treatment market during the forecast period. Germany is becoming increasingly popular when it comes to health and innovation. With the surging prevalence of influenza A (H1), as well as increasing surveillance and management measures of the disease implemented by the World Health Organization (WHO), the demand for swine respiratory disease treatment options will grow at a rapid pace.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Mycoplasma-based Swine Diseases to Exhibit High Growth in the Upcoming Decade
Mycoplasma-based causative agents are expected to witness high growth at a CAGR of 6.1% by the end of the forecast period. The segment held a swine respiratory diseases treatment market share of about 35.2% in 2021. The major pathogen of enzootic pneumonia, a chronic respiratory disease in pigs, is mycoplasma hyopneumoniae. Infections caused by mycoplasma hyopneumoniae are common in practically all swine production locations, which leads to huge economic losses due to increased medicine consumption and lower pig performance.
Common Swine Diseases Are Expected to Be Treated with Antibiotics
The drugs segment is expected to create high growth at a CAGR of 6.1% by the end of the forecast period. The segment held a swine respiratory diseases treatment market share of about 63.8% in 2021. Antibiotic use during all stages of growth enhances the efficiency and efficacy of body weight gain, lowers death rates & comorbidities, reduces subclinical disease, and improves pig health.
Veterans Prefer Oral Route of Administration to Treat Swine Fever Disease
The oral route of administration is expected to exhibit high growth at a CAGR of 6.3% by the end of the forecast period. The segment held a swine respiratory diseases treatment market share of about 86.3% in 2021. The oral route of administration is the most common form of medication administration in farm animals. Medications are mixed with animal feed for ease of ingestion, which would push the segment.
Veterinary Hospitals to Offer Advanced Treatment Options for Swine Bacterial Diseases
Veterinary hospitals held the highest swine respiratory diseases treatment market share of 37.0% in 2021. Pigs are considered to be better medical research subjects than mice as their size, physiology, and genetic makeup are more similar to humans.
With several competitors in the swine respiratory diseases treatment market, the overall industry is highly fragmented. To meet rising consumer demand and expand their customer base, these companies are implementing various methods such as mergers & acquisitions, partnerships & collaborations, and new product launches.
Some of the recent developments in the swine respiratory diseases treatment market are given below:
| Attribute | Details |
|---|---|
| Estimated Market Size (2022) | US$ 1,978.1 Million |
| Projected Market Valuation (2032) | US$ 3,649.5 Million |
| Value-based CAGR (2022 to 2032) | 6.3% |
| Forecast Period | 2012 to 2021 |
| Historical Data Available for | 2022 to 2032 |
| Market Analysis | Value (US$ Million) |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, Nordic Countries, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC, North Africa, and South Africa |
| Key Market Segments Covered | Causative Agent, Treatment, Route of Administration, Distribution Channel, and Region |
| Key Companies Profiled | Zoetis; Bayer AG; Boehringer Ingelheim GmbH; Elanco Animal Health (Sub. Eli Lilly); Virbac; Norbrook; Ceva Santé Animale; Intervet Inc., (Sub. Merck & Co. Inc.); Vetoquinol SA; Bimeda Inc.; Kyoritsu Seiyaku Corporation; HIPRA; Agrilabs, Inc.; Ashish LifeSciences Ltd.; Cipla Pharmaceuticals.; Thermo Fisher Scientific Inc.; Huvepharma |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, Drivers, Restraints, Opportunities and Threats Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
The global swine respiratory diseases treatment market was worth US$ 1,852.0 Million in 2021 and is set to expand 1.8x over the next ten years.
The swine respiratory diseases treatment market is expected to reach US$ 3,649.5 Million by the end of 2032, with sales revenue set to register a 6.3% CAGR.
Emergence of biologics & specialty care, growing awareness & affordability of therapeutics for livestock, and shifting distribution of drugs from traditional channels are some of the key trends in the swine respiratory diseases treatment market.
The USA, Canada, China, the Philippines, and South Korea are expected to drive demand in the swine respiratory diseases treatment market.
North America is one of the key regions, with the USA accounting for about 52.9% of the region’s swine respiratory diseases treatment market in the year 2021.
The swine respiratory disease treatment market in Japan is expected to register growth at a CAGR of 5.2% over the next ten years.
The swine respiratory disease treatment market in Germany is expected to register growth at a CAGR of 5.8% over the next ten years.
China, the USA, and the Philippines are the key producers of swine respiratory diseases treatment
Zoetis, Bayer AG, Boehringer Ingelheim GmbH, Elanco Animal Health (Sub. Eli Lilly), Virbac, Norbrook, Ceva Santé Animale, Intervet Inc. (Sub. Merck & Co. Inc.), Vetoquinol SA, Bimeda, Inc., Kyoritsu Seiyaku Corporation, HIPRA, Agrilabs, Inc., Ashish LifeSciences Ltd., Cipla Pharmaceuticals., Thermo Fisher Scientific Inc., and Huvepharma, are some of the key players in the swine respiratory diseases treatment market.
The global swine respiratory disease treatment market in South Korea is expected to register growth at a CAGR of 6.1% over the next ten years.
1. Executive Summary | Swine Respiratory Diseases Treatment Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Disease Epidemiology
4.2. Key Promotional Strategies - by Manufacturers
4.3. Regulatory Scenario
4.4. Reimbursement Scenario
4.5. Porter’s Analysis
4.6. PESTLE Analysis
4.7. Value Chain Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Outlook
5.1.3. Global Veterinary Services Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. New Product Launches
5.2.2. Rise in Consumption of Pork
5.2.3. Increasing Requirement of Quality of Life in Animal Healthcare
5.2.4. Increasing Research and Development Activities
5.2.5. Adoption of Veterinary Vaccination
5.2.6. Introduction of Novel and Advanced Technologies
5.2.7. Government Investments in Veterinary Diseases
5.2.8. Increasing Prevalence of Porcine Reproductive and Respiratory Syndrome
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. By Causative Agent
6.1.2. By Treatment
6.1.3. By Route of Administration
6.1.4. By Distribution Channel
6.1.5. By Country
6.2. 2021 Market Scenario
7. Global Market Demand (in Value or Size in US$ Million) Analysis 2012 to 2021 and Forecast, 2022 to 2032
7.1. Historical Market Value (US$ Million) Analysis, 2012 to 2021
7.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Causative Agent
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis and Forecast By Causative Agent, 2012 to 2021
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Causative Agent, 2022 to 2032
8.3.1. Virus
8.3.2. Mycoplasma
8.3.3. Bacteria
8.3.4. Others
8.4. Market Attractiveness Analysis By Causative Agent
9. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Treatment
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis By Treatment, 2012 to 2021
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Treatment, 2022 to 2032
9.3.1. Drugs
9.3.1.1. Antibiotics
9.3.1.2. Others
9.3.2. Vaccines
9.4. Market Attractiveness Analysis By Treatment
10. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Route of Administration
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis, By Route of Administration, 2012 to 2021
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Route of Administration, 2022 to 2032
10.3.1. Oral
10.3.2. Parenteral
10.4. Market Attractiveness Analysis By Route of Administration
11. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Distribution Channel
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis, By Distribution Channel, 2012 to 2021
11.3. Current and Future Market Size (US$ Million) Analysis Forecast By Distribution Channel, 2022 to 2032
11.3.1. Veterinary Hospitals
11.3.2. Veterinary Clinics
11.3.3. Pharmacies
11.3.4. Others
11.4. Market Attractiveness Analysis By Distribution Channel
12. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Region
12.1. Introduction
12.2. Historical Market Size (US$ Million) Analysis By Region, 2012 to 2021
12.3. Current Market Size (US$ Million) Analysis and Forecast By Region, 2022 to 2032
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. East Asia
12.3.5. South Asia
12.3.6. Oceania
12.3.7. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis By Region
13. North America Market Analysis 2012 to 2021 and Forecast 2022 to 2032
13.1. Introduction
13.2. Pricing Analysis
13.3. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021
13.4. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032
13.4.1. By Country
13.4.1.1. United States of America
13.4.1.2. Canada
13.4.2. By Causative Agent
13.4.3. By Treatment
13.4.4. By Route of Administration
13.4.5. By Distribution Channel
13.5. Market Attractiveness Analysis
13.5.1. By Country
13.5.2. By Causative Agent
13.5.3. By Treatment
13.5.4. By Route of Administration
13.5.5. By Distribution Channel
13.6. Market Trends
13.7. Key Market Participants - Intensity Mapping
13.8. Drivers and Restraints - Impact Analysis
13.9. Country-Level Analysis & Forecast
13.9.1. USA Market Analysis
13.9.1.1. .Introduction
13.9.1.2. Market Analysis and Forecast by Market Taxonomy
13.9.1.2.1. By Causative Agent
13.9.1.2.2. By Treatment
13.9.1.2.3. By Route of Administration
13.9.1.2.4. By Distribution Channel
13.9.2. Canada Market Analysis
13.9.2.1. Introduction
13.9.2.2. Market Analysis and Forecast by Market Taxonomy
13.9.2.2.1. By Causative Agent
13.9.2.2.2. By Treatment
13.9.2.2.3. By Route of Administration
13.9.2.2.4. By Distribution Channel
14. Latin America Market Analysis 2012 to 2021 and Forecast 2022 to 2032
14.1. Introduction
14.2. Pricing Analysis
14.3. Historical Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2012 to 2021
14.4. Current and Future Market Size (US$ Million) Analysis Forecast By Market Taxonomy, 2022 to 2032
14.4.1. By Country
14.4.1.1. Mexico
14.4.1.2. Brazil
14.4.1.3. Argentina
14.4.1.4. Rest of Latin America
14.4.2. By Causative Agent
14.4.3. By Treatment
14.4.4. By Route of Administration
14.4.5. By Distribution Channel
14.5. Market Attractiveness Analysis
14.5.1. By Country
14.5.2. By Causative Agent
14.5.3. By Treatment
14.5.4. By Route of Administration
14.5.5. By Distribution Channel
14.6. Market Trends
14.7. Key Market Participants - Intensity Mapping
14.8. Drivers and Restraints - Impact Analysis
14.9. Country-Level Analysis & Forecast
14.9.1. Mexico Market Analysis
14.9.1.1. Introduction
14.9.1.2. Market Analysis and Forecast by Market Taxonomy
14.9.1.2.1. By Causative Agent
14.9.1.2.2. By Treatment
14.9.1.2.3. By Route of Administration
14.9.1.2.4. By Distribution Channel
14.9.2. Brazil Market Analysis
14.9.2.1. Introduction
14.9.2.2. Market Analysis and Forecast by Market Taxonomy
14.9.2.2.1. By Causative Agent
14.9.2.2.2. By Treatment
14.9.2.2.3. By Route of Administration
14.9.2.2.4. By Distribution Channel
14.9.3. Argentina Market Analysis
14.9.3.1. Introduction
14.9.3.2. Market Analysis and Forecast by Market Taxonomy
14.9.3.2.1. By Causative Agent
14.9.3.2.2. By Treatment
14.9.3.2.3. By Route of Administration
14.9.3.2.4. By Distribution Channel
15. Europe Market Analysis 2012 to 2021 and Forecast 2022 to 2032
15.1. Introduction
15.2. Pricing Analysis
15.3. Historical Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2012 to 2021
15.4. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032
15.4.1. By Country
15.4.1.1. Germany
15.4.1.2. Italy
15.4.1.3. France
15.4.1.4. United Kingdom
15.4.1.5. Spain
15.4.1.6. BENELUX
15.4.1.7. Russia
15.4.1.8. Nordic Countries
15.4.1.9. Rest of Europe
15.4.2. By Causative Agent
15.4.3. By Treatment
15.4.4. By Route of Administration
15.4.5. By Distribution Channel
15.5. Market Attractiveness Analysis
15.5.1. By Country
15.5.2. By Causative Agent
15.5.3. By Treatment
15.5.4. By Route of Administration
15.5.5. By Distribution Channel
15.6. Market Trends
15.7. Key Market Participants - Intensity Mapping
15.8. Drivers and Restraints - Impact Analysis
15.9. Country-Level Analysis & Forecast
15.9.1. Germany Market Analysis
15.9.1.1. Introduction
15.9.1.2. Market Analysis and Forecast by Market Taxonomy
15.9.1.2.1. By Causative Agent
15.9.1.2.2. By Treatment
15.9.1.2.3. By Route of Administration
15.9.1.2.4. By Distribution Channel
15.9.2. Italy Market Analysis
15.9.2.1. Introduction
15.9.2.2. Market Analysis and Forecast by Market Taxonomy
15.9.2.2.1. By Causative Agent
15.9.2.2.2. By Treatment
15.9.2.2.3. By Route of Administration
15.9.2.2.4. By Distribution Channel
15.9.3. France Market Analysis
15.9.3.1. Introduction
15.9.3.2. Market Analysis and Forecast by Market Taxonomy
15.9.3.2.1. By Causative Agent
15.9.3.2.2. By Treatment
15.9.3.2.3. By Route of Administration
15.9.3.2.4. By Distribution Channel
15.9.4. UK Market Analysis
15.9.4.1. Introduction
15.9.4.2. Market Analysis and Forecast by Market Taxonomy
15.9.4.2.1. By Causative Agent
15.9.4.2.2. By Treatment
15.9.4.2.3. By Route of Administration
15.9.4.2.4. By Distribution Channel
15.9.5. Spain Market Analysis
15.9.5.1. Introduction
15.9.5.2. Market Analysis and Forecast by Market Taxonomy
15.9.5.2.1. By Causative Agent
15.9.5.2.2. By Treatment
15.9.5.2.3. By Route of Administration
15.9.5.2.4. By Distribution Channel
15.9.6. BENELUX Market Analysis
15.9.6.1. Introduction
15.9.6.2. Market Analysis and Forecast by Market Taxonomy
15.9.6.2.1. By Causative Agent
15.9.6.2.2. By Treatment
15.9.6.2.3. By Route of Administration
15.9.6.2.4. By Distribution Channel
15.9.7. Russia Market Analysis
15.9.7.1. Introduction
15.9.7.2. Market Analysis and Forecast by Market Taxonomy
15.9.7.2.1. By Causative Agent
15.9.7.2.2. By Treatment
15.9.7.2.3. By Route of Administration
15.9.7.2.4. By Distribution Channel
15.9.8. Nordic Countries Market Analysis
15.9.8.1. Introduction
15.9.8.2. Market Analysis and Forecast by Market Taxonomy
15.9.8.2.1. By Causative Agent
15.9.8.2.2. By Treatment
15.9.8.2.3. By Route of Administration
15.9.8.2.4. By Distribution Channel
16. East Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032
16.1. Introduction
16.2. Pricing Analysis
16.3. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021
16.4. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032
16.4.1. By Country
16.4.1.1. China
16.4.1.2. Japan
16.4.1.3. South Korea
16.4.2. By Causative Agent
16.4.3. By Treatment
16.4.4. By Route of Administration
16.4.5. By Distribution Channel
16.5. Market Attractiveness Analysis
16.5.1. By Country
16.5.2. By Causative Agent
16.5.3. By Treatment
16.5.4. By Route of Administration
16.5.5. By Distribution Channel
16.6. Market Trends
16.7. Key Market Participants - Intensity Mapping
16.8. Drivers and Restraints - Impact Analysis
16.9. Country-Level Analysis & Forecast
16.9.1. China Market Analysis
16.9.1.1. Introduction
16.9.1.2. Market Analysis and Forecast by Market Taxonomy
16.9.1.2.1. By Causative Agent
16.9.1.2.2. By Treatment
16.9.1.2.3. By Route of Administration
16.9.1.2.4. By Distribution Channel
16.9.2. Japan Market Analysis
16.9.2.1. Introduction
16.9.2.2. Market Analysis and Forecast by Market Taxonomy
16.9.2.2.1. By Causative Agent
16.9.2.2.2. By Treatment
16.9.2.2.3. By Route of Administration
16.9.2.2.4. By Distribution Channel
16.9.3. South Korea Market Analysis
16.9.3.1. Introduction
16.9.3.2. Market Analysis and Forecast by Market Taxonomy
16.9.3.2.1. By Causative Agent
16.9.3.2.2. By Treatment
16.9.3.2.3. By Route of Administration
16.9.3.2.4. By Distribution Channel
17. South Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032
17.1. Introduction
17.2. Pricing Analysis
17.3. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021
17.4. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032
17.4.1. By Country
17.4.1.1. India
17.4.1.2. Indonesia
17.4.1.3. Malaysia
17.4.1.4. Thailand
17.4.1.5. Rest of South Asia
17.4.2. By Causative Agent
17.4.3. By Treatment
17.4.4. By Route of Administration
17.4.5. By Distribution Channel
17.5. Market Attractiveness Analysis
17.5.1. By Country
17.5.2. By Causative Agent
17.5.3. By Treatment
17.5.4. By Route of Administration
17.5.5. By Distribution Channel
17.6. Market Trends
17.7. Key Market Participants - Intensity Mapping
17.8. Drivers and Restraints - Impact Analysis
17.9. Country-Level Analysis & Forecast
17.9.1. India Market Analysis
17.9.1.1. Introduction
17.9.1.2. Market Analysis and Forecast by Market Taxonomy
17.9.1.2.1. By Causative Agent
17.9.1.2.2. By Treatment
17.9.1.2.3. By Route of Administration
17.9.1.2.4. By Distribution Channel
17.9.2. Indonesia Market Analysis
17.9.2.1. Introduction
17.9.2.2. Market Analysis and Forecast by Market Taxonomy
17.9.2.2.1. By Causative Agent
17.9.2.2.2. By Treatment
17.9.2.2.3. By Route of Administration
17.9.2.2.4. By Distribution Channel
17.9.3. Malaysia Market Analysis
17.9.3.1. Introduction
17.9.3.2. Market Analysis and Forecast by Market Taxonomy
17.9.3.2.1. By Causative Agent
17.9.3.2.2. By Treatment
17.9.3.2.3. By Route of Administration
17.9.3.2.4. By Distribution Channel
17.9.4. Thailand Market Analysis
17.9.4.1. Introduction
17.9.4.2. Market Analysis and Forecast by Market Taxonomy
17.9.4.2.1. By Causative Agent
17.9.4.2.2. By Treatment
17.9.4.2.3. By Route of Administration
17.9.4.2.4. By Distribution Channel
17.9.5. Rest of South Asia Market Analysis
17.9.5.1. Introduction
17.9.5.2. Market Analysis and Forecast by Market Taxonomy
17.9.5.2.1. By Causative Agent
17.9.5.2.2. By Treatment
17.9.5.2.3. By Route of Administration
17.9.5.2.4. By Distribution Channel
18. Oceania Market 2012 to 2021 and Forecast 2022 to 2032
18.1. Introduction
18.2. Pricing Analysis
18.3. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021
18.4. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032
18.4.1. By Country
18.4.1.1. Australia
18.4.1.2. New Zealand
18.4.2. By Causative Agent
18.4.3. By Treatment
18.4.4. By Route of Administration
18.4.5. By Distribution Channel
18.5. Market Attractiveness Analysis
18.5.1. By Country
18.5.2. By Causative Agent
18.5.3. By Treatment
18.5.4. By Route of Administration
18.5.5. By Distribution Channel
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country-Level Analysis & Forecast
18.8.1. Australia Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Causative Agent
18.8.1.2.2. By Treatment
18.8.1.2.3. By Route of Administration
18.8.1.2.4. By Distribution Channel
18.8.2. New Zealand Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Causative Agent
18.8.2.2.2. By Treatment
18.8.2.2.3. By Route of Administration
18.8.2.2.4. By Distribution Channel
19. Middle East and Africa (MEA) Market Analysis 2012 to 2021 and Forecast 2022 to 2032
19.1. Introduction
19.2. Pricing Analysis
19.3. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021
19.4. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032
19.4.1. By Country
19.4.1.1. GCC Countries
19.4.1.2. Turkey
19.4.1.3. South Africa
19.4.1.4. North Africa
19.4.1.5. Rest of Middle East and Africa
19.4.2. By Causative Agent
19.4.3. By Treatment
19.4.4. By Route of Administration
19.4.5. By Distribution Channel
19.5. Market Attractiveness Analysis
19.5.1. By Country
19.5.2. By Causative Agent
19.5.3. By Treatment
19.5.4. By Route of Administration
19.5.5. By Distribution Channel
19.6. Market Trends
19.7. Key Market Participants - Intensity Mapping
19.8. Drivers and Restraints - Impact Analysis
19.9. Country-Level Analysis & Forecast
19.9.1. GCC Countries Market Analysis
19.9.1.1. Introduction
19.9.1.2. Market Analysis and Forecast by Market Taxonomy
19.9.1.2.1. By Causative Agent
19.9.1.2.2. By Treatment
19.9.1.2.3. By Route of Administration
19.9.1.2.4. By Distribution Channel
19.9.2. Turkey Market Analysis
19.9.2.1. Introduction
19.9.2.2. Market Analysis and Forecast by Market Taxonomy
19.9.2.2.1. By Causative Agent
19.9.2.2.2. By Treatment
19.9.2.2.3. By Route of Administration
19.9.2.2.4. By Distribution Channel
19.9.3. South Africa Market Analysis
19.9.3.1. Introduction
19.9.3.2. Market Analysis and Forecast by Market Taxonomy
19.9.3.2.1. By Causative Agent
19.9.3.2.2. By Treatment
19.9.3.2.3. By Route of Administration
19.9.3.2.4. By Distribution Channel
19.9.4. North Africa Market Analysis
19.9.4.1. Introduction
19.9.4.2. Market Analysis and Forecast by Market Taxonomy
19.9.4.2.1. By Causative Agent
19.9.4.2.2. By Treatment
19.9.4.2.3. By Route of Administration
19.9.4.2.4. By Distribution Channel
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Concentration
20.3. Market Share Analysis of Top Players
20.4. Market Presence Analysis
20.4.1. By Regional footprint of Players
20.4.2. Product foot print by Players
20.4.3. Channel Foot Print by Players
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive
21.3.1. Zoetis
21.3.1.1. Overview
21.3.1.2. Product Portfolio
21.3.1.3. Profitability by Market Segments (Product/Channel/Region)
21.3.1.4. Sales Footprint
21.3.1.5. Key Financials
21.3.1.6. SWOT Analysis
21.3.1.7. Strategy Overview
21.3.2. Bayer AG
21.3.2.1. Overview
21.3.2.2. Product Portfolio
21.3.2.3. Profitability by Market Segments (Product/Channel/Region)
21.3.2.4. Sales Footprint
21.3.2.5. Key Financials
21.3.2.6. SWOT Analysis
21.3.2.7. Strategy Overview
21.3.3. Boehringer Ingelheim GmbH
21.3.3.1. Overview
21.3.3.2. Product Portfolio
21.3.3.3. Profitability by Market Segments (Product/Channel/Region)
21.3.3.4. Sales Footprint
21.3.3.5. Key Financials
21.3.3.6. SWOT Analysis
21.3.3.7. Strategy Overview
21.3.4. Elanco Animal Health (Sub. Eli Lilly)
21.3.4.1. Overview
21.3.4.2. Product Portfolio
21.3.4.3. Profitability by Market Segments (Product/Channel/Region)
21.3.4.4. Sales Footprint
21.3.4.5. Key Financials
21.3.4.6. SWOT Analysis
21.3.4.7. Strategy Overview
21.3.5. Virbac
21.3.5.1. Overview
21.3.5.2. Product Portfolio
21.3.5.3. Profitability by Market Segments (Product/Channel/Region)
21.3.5.4. Sales Footprint
21.3.5.5. Key Financials
21.3.5.6. SWOT Analysis
21.3.5.7. Strategy Overview
21.3.6. Norbrook
21.3.6.1. Overview
21.3.6.2. Product Portfolio
21.3.6.3. Profitability by Market Segments (Product/Channel/Region)
21.3.6.4. Sales Footprint
21.3.6.5. Key Financials
21.3.6.6. SWOT Analysis
21.3.6.7. Strategy Overview
21.3.7. Ceva Santé Animale
21.3.7.1. Overview
21.3.7.2. Product Portfolio
21.3.7.3. Profitability by Market Segments (Product/Channel/Region)
21.3.7.4. Sales Footprint
21.3.7.5. Key Financials
21.3.7.6. SWOT Analysis
21.3.7.7. Strategy Overview
21.3.8. Intervet Inc., (Sub. Merck & Co. Inc.)
21.3.8.1. Overview
21.3.8.2. Product Portfolio
21.3.8.3. Profitability by Market Segments (Product/Channel/Region)
21.3.8.4. Sales Footprint
21.3.8.5. Key Financials
21.3.8.6. SWOT Analysis
21.3.8.7. Strategy Overview
21.3.9. Vetoquinol SA
21.3.9.1. Overview
21.3.9.2. Product Portfolio
21.3.9.3. Profitability by Market Segments (Product/Channel/Region)
21.3.9.4. Sales Footprint
21.3.9.5. Key Financials
21.3.9.6. SWOT Analysis
21.3.9.7. Strategy Overview
21.3.10. Bimeda Inc.,
21.3.10.1. Overview
21.3.10.2. Product Portfolio
21.3.10.3. Profitability by Market Segments (Product/Channel/Region)
21.3.10.4. Sales Footprint
21.3.10.5. Key Financials
21.3.10.6. SWOT Analysis
21.3.10.7. Strategy Overview
21.3.11. Kyoritsu Seiyaku Corporation
21.3.11.1. Overview
21.3.11.2. Product Portfolio
21.3.11.3. Profitability by Market Segments (Product/Channel/Region)
21.3.11.4. Sales Footprint
21.3.11.5. Key Financials
21.3.11.6. SWOT Analysis
21.3.11.7. Strategy Overview
21.3.12. HIPRA
21.3.12.1. Overview
21.3.12.2. Product Portfolio
21.3.12.3. Profitability by Market Segments (Product/Channel/Region)
21.3.12.4. Sales Footprint
21.3.12.5. Key Financials
21.3.12.6. SWOT Analysis
21.3.12.7. Strategy Overview
21.3.13. Agrilabs, Inc.,
21.3.13.1. Overview
21.3.13.2. Product Portfolio
21.3.13.3. Profitability by Market Segments (Product/Channel/Region)
21.3.13.4. Sales Footprint
21.3.13.5. Key Financials
21.3.13.6. SWOT Analysis
21.3.13.7. Strategy Overview
21.3.14. Ashish Lifesciences Ltd.,
21.3.14.1. Overview
21.3.14.2. Product Portfolio
21.3.14.3. Profitability by Market Segments (Product/Channel/Region)
21.3.14.4. Sales Footprint
21.3.14.5. Key Financials
21.3.14.6. SWOT Analysis
21.3.14.7. Strategy Overview
21.3.15. Cipla Pharmaceuticals.
21.3.15.1. Overview
21.3.15.2. Product Portfolio
21.3.15.3. Profitability by Market Segments (Product/Channel/Region)
21.3.15.4. Sales Footprint
21.3.15.5. Key Financials
21.3.15.6. SWOT Analysis
21.3.15.7. Strategy Overview
21.3.16. Thermo Fisher Scientific Inc.,
21.3.16.1. Overview
21.3.16.2. Product Portfolio
21.3.16.3. Profitability by Market Segments (Product/Channel/Region)
21.3.16.4. Sales Footprint
21.3.16.5. Key Financials
21.3.16.6. SWOT Analysis
21.3.16.7. Strategy Overview
21.3.17. Huvepharma.
21.3.17.1. Overview
21.3.17.2. Product Portfolio
21.3.17.3. Profitability by Market Segments (Product/Channel/Region)
21.3.17.4. Sales Footprint
21.3.17.5. Key Financials
21.3.17.6. SWOT Analysis
21.3.17.7. Strategy Overview
22. Assumptions and Acronyms Used
23. Research Methodology
Explore Healthcare Insights
View Reports
Swine Respiratory Diseases Treatment Market
